(Q42740868)

6 November 2017

Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib (English)

1 reference

6 November 2017

hepatocellular carcinoma

1 reference

2

1 reference

6 November 2017

Armando Santoro

6

1 reference

ORCID Public Data File 2021

author name string

Giovanni Abbadessa

1

1 reference

6 November 2017

Tiziana Pressiani

3

1 reference

6 November 2017

Cynthia Carrillo-Infante

4

1 reference

6 November 2017

Emanuele Cucchi

5

1 reference

6 November 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

World Journal of Gastroenterology

6 November 2017

1 reference

6 November 2017

17

1 reference

6 November 2017

19

1 reference

6 November 2017

2450-2453

1 reference

The present and the future landscape of treatment of advanced hepatocellular carcinoma.

6 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Sorafenib in advanced hepatocellular carcinoma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Design and endpoints of clinical trials in hepatocellular carcinoma.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3103800

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21633647

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21633647

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3748/WJG.V17.I19.2450

1 reference

6 November 2017

1 reference

6 November 2017

PubMed publication ID

21633647

1 reference